Evidence map›Paper›PMID 32918658›Full record

ReviewBreast cancer research and treatment2020

Treatment interruption and discontinuation of hormonal therapy in hormone receptor-positive breast cancer patients.

Daqin Mao, Hilal Hachem, Hong Chang, Danai Dima, Joshua Dower, Michael Wismer, John K Erban, Karen M Freund, Susan K Parsons

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Breast cancer research and treatment, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Daqin MaoTufts Clinical and Translational Science Institute (CTSI), Boston, MA, 02111, USA.
Hilal HachemDivision of Hematology/Oncology, Tufts Medical Center, Boston, MA, 02111, USA.
Hong ChangTufts Clinical and Translational Science Institute (CTSI), Boston, MA, 02111, USA.
Danai DimaDepartment of Medicine, Tufts Medical Center, 800 Washington St. #345, Boston, MA, 02111, USA.
Joshua DowerDepartment of Medicine, Tufts Medical Center, 800 Washington St. #345, Boston, MA, 02111, USA.
Michael WismerDepartment of Medicine, Tufts Medical Center, 800 Washington St. #345, Boston, MA, 02111, USA.
John K ErbanDivision of Hematology/Oncology, Tufts Medical Center, Boston, MA, 02111, USA.
Karen M FreundTufts Clinical and Translational Science Institute (CTSI), Boston, MA, 02111, USA.
Susan K ParsonsTufts Clinical and Translational Science Institute (CTSI), Boston, MA, 02111, USA. sparsons@tuftsmedicalcenter.org.ORCID http://orcid.org/0000-0003-0282-6490
Tufts Medical Center · USSouthern California Clinical and Translational Science Institute · USTufts University · US

Funding

Tufts Clinical and Translational Research InstituteTL1TR001062 · NCATS · TUFTS UNIVERSITY BOSTON · PI SELKER, HARRY P. · 2013 to 2017
$2.1M
American Cancer Society CRP-17-112-06-COUNNational Center for Advancing Translational Sciences (US) TL1TR001062NCATS NIH HHS TL1 TR001062Susan G. Komen for the Cure Training Grant in Health Disparities GTDR15333918
6 · The paper itself

Abstract

purposeTo investigate predictors of treatment interruption and early discontinuation of adjuvant hormonal therapy (HT) in a retrospective cohort of women with newly diagnosed hormone receptor-positive (HR +) breast cancer.

methodsEligible cases were identified from a single institutional tumor registry from 2009 to 2015. Patients were followed from initiation of adjuvant HT for a minimum of one year through December 1, 2016. Predictors of treatment interruption or early discontinuation were analyzed with Cox proportional hazards regression models.

resultsWith a median follow-up time of 3.0 years (IQR 1.5-4.5), 22 women (10.9%) discontinued HT early and 47 (23.4%) had at least one treatment interruption of > 14 days. Adjusted Cox proportional hazards regression models showed that women with pre-existing affective disorders were more likely to discontinue therapy early (HR 3.15; 95% CI 1.35-7.37), while those with pre-existing chronic pain disorders were at increased risk for treatment interruption (HR 2.24; 95% CI 1.20-4.19). HT-related symptoms were the most commonly reported reason for HT interruption or discontinuation. Women who experienced severe treatment-related symptoms were at increased risk for both HT interruption (HR 2.64; 95% CI 1.07-6.50) and HT discontinuation (HR 3.48; 95% CI 1.20-10.1).

conclusionsThis study showed that HT interruptions and discontinuation were common, often associated with HT-related symptoms. Clinicians caring for breast cancer patients on HT should monitor closely for treatment-emergent symptoms, especially women with pre-existing disorders, and support them to continue therapy through aggressive symptom management and other patient-centered approaches.

Indexed as

Breast NeoplasmsAntineoplastic Agents, HormonalChemotherapy, AdjuvantFemaleHormonesHumansMedication AdherenceRetrospective StudiesAntineoplastic Agents, HormonalHormonesAdjuvant hormonal therapyMedication adherenceSymptomsTreatment interruption and discontinuation

Identifiers

PMID32918658
PMCPMC11372730
OpenAlexW3085403951

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.